This phase III trial is trying to determine how safe and effective an immunotherapy drug (pembrolizumab) is, when it is given alone and in combination with an oral drug (lenvatinib), as a first line treatment for patients with advanced melanoma.
This trial is treating patients with melanoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma
Eligible participants will be randomised to receive a 200mg intravenous infusion of pembrolizumab on Day 1 of each 3-week cycle and 20mg oral levatinib OR placebo daily for up to two years.
Recruiting Hospitals Read More